Cancer Stem Cell News Volume 4.07 | Feb 25 2015

Hyperthermia Sensitizes Glioma Stem-Like Cells to Radiation by Inhibiting AKT Signaling
Scientists investigated the mechanisms of hyperthermic radiosensitization in glioma stem-like cells by a phospho-kinase array that revealed the survival kinase AKT as a critical sensitization determinant. [Cancer Res] Abstract

Radiosensitization of Primary Human Glioblastoma Stem-Like Cells with Low-Dose AKT Inhibition
Scientists demonstrate that in primary glioblastoma (GBM) tumor samples, full-dose inhibition of AKT activity leads to differential responses among samples in the context of cell death and self- renewal, reinforcing the notion that GBM is a heterogeneous disease. [Mol Cancer Ther] Abstract

Enhancing HOTAIR/MiR-10b Drive Liver Normal Stem Cells to Arise Malignant Transformation Tendency through Inducing Epithelial-Mesenchymal Transitions
After microRNA-10b and HOTAIR were separately enhanced, several cancer stem cell-like traits appeared in the liver normal stem cells, such as in vitro enhanced proliferative capacity, expression of putative liver cancer stem cells markers, progressed obtainment of invasive ability, and even in vivo aggravation into and taking place of normal liver tissue. [Rejuvenation Res] Abstract

Dicer Regulated Let-7 Expression Levels in p53-Induced Cancer Repression Requires Cyclin D1
Researchers found that let-7 miRNA expression decreased because of the p53-induced cell death response with deregulated cyclin D1. Their results also showed that cyclin D1 is required for altered Nutlin-3- and TAX-induced let-7 expression in cancer repression and the cell death response. [J Cell Mol Med] Full Article

Natural Grape Extracts Regulate Colon Cancer Cells Malignancy
Liofenol^™ induced an important morphology change in HCT116 cells, migration inhibition, undifferentiated stem/stem-like cells markers downregulation, and E-cadherin downregulation, interested in epithelia to mesenchymal malignant transition. [Nutr Cancer] Abstract

Prognostic Significance of CD44v6, CD133, CD166, and ALDH1 Expression in Small Intestinal Adenocarcinoma
CD44v6, CD133, CD166, and ALDH1 have been proposed to be putative cancer stem cell markers in gastrointestinal malignancies. Researchers investigated the expressions of CD44v6, CD133, CD166, and ALDH1 and evaluated their relationships with clinicopathologic parameters including the survival data in small intestinal adenocarcinoma. [Appl Immunohistochem Mol Morphol] Abstract

A Progesterone-CXCR4 Axis Controls Mammary Progenitor Cell Fate in the Adult Gland CXCR4 Function in Mammary Progenitors
Scientists demonstrate that CXCR4, the receptor for stromal-derived factor 1, is a crucial instructor of hormone-induced mammary stem and progenitor cell function and present a new avenue for potentially targeting progenitor cell growth and malignant transformation in breast cancer. [Stem Cell Rep]
Full Article | Graphical Abstract

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

MD Anderson Joins CATCH^® Global Foundation to Boost Child Health, Prevent Cancer in Later Years
The University of Texas System Board of Regents approved the agreement that makes MD Anderson a founding partner in the foundation. Coordinated Approach to Child Health (CATCH^®) is a program developed and disseminated by The University of Texas Health Science Center at Houston School of Public Health. [The University of Texas MD Anderson Cancer Center] Press Release

Celldex’s Rindopepimut (Rintega^®) Receives FDA Breakthrough Therapy Designation for the Treatment of Adult Patients with EGFRvIII-positive Glioblastoma
Celldex Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted rindopepimut (Rintega^®) breakthrough therapy designation for the treatment of adult patients with EGFRvIII-positive glioblastoma. [Celldex Therapeutics, Inc.] Press Release

From our sponsor: Free mouse hematopoietic progenitors wallchart. Request your copy.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the cancer stem cell community.

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Research Technician II – Pediatric Cancer and Stem Cells (Massachusetts General Hospital)

Director – Vector Production (Sangamo BioSciences, Inc.)

Senior Process Development Engineer (Sangamo BioSciences, Inc.)

Postdoctoral Fellow – Stem Cells and Breast Cancer (Albert Einstein College of Medicine)

Junior Group Leaders – Cell Biology of Cancer and Genomic Instability (Foundation FIRC Institute of Molecular Oncology)

Postdoctoral Position – Stem Cell Biology/Cancer Biology (Oregon Health & Science University)

Postdoctoral Positions – Cancer Bioengineering and Cancer Biology (University of Minnesota)

Postdoctoral Fellow – Wnt Signaling in Development and Disease (Van Andel Research Institute)

Postdoctoral Research Fellow – Post-Transcriptional Gene Regulation Governing Cancer Cell Behavior (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.